All stock lists
Erasca, Inc. (NASDAQ:ERAS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
15.48-0.13 (-0.83%)
Market cap
$5.41B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 16, 2021
Website
Insider Score
––Not scored
ERAS Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From ERAS’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$287.2M
- Net margin
- —
Leverage19 / 20
Little or no net debt.
- Total debt
- $44.7M
- Cash
- $42.5M
- Debt / equity
- 0.12
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $278.4M
- Current liabilities
- $33.6M
- Current ratio
- 8.29
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$98.0M
- Free cash flow
- -$98.1M
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 311.3M
- Share growth (1y)
- 9.9%
- Cash runway
- 5 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ERAS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 723.00 K | 743.00 K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -723.00 K | -743.00 K | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 11.72 M | 10.65 M | 9.36 M | 10.07 M | 9.46 M | 9.66 M |
| R&D Expense | 35.90 M | 27.27 M | 23.24 M | 22.47 M | 21.17 M | 25.97 M |
| Operating Expenses | 47.62 M | 37.19 M | 31.86 M | 34.55 M | 38.13 M | 35.63 M |
| Operating Income | -47.62 M | -37.91 M | -32.60 M | -34.55 M | -38.13 M | -35.63 M |
| Pretax Income | -44.08 M | -183.44 M | -29.09 M | -30.61 M | -33.88 M | -30.97 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -44.08 M | -183.44 M | -29.09 M | -30.61 M | -33.88 M | -30.97 M |
| EPS (Basic) | -0.14 | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 |
| EPS (Diluted) | -0.14 | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 |
| Shares Outstanding | 311.34 M | 304.32 M | 283.53 M | 283.68 M | 283.36 M | 283.26 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.